A Path or a New Road in Laboratory Diagnostics? Biological Mass Spectrometry: Facts and Perspectives

Gábor ELEK1, Károly LAPIS2

1Department of Pathology, Kútvölgyi Clinical Center, Semmelweis University, Budapest, Hungary
21st Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary


Proteins in tissues and biofluids and their many attributes define the proteome. Proteome can be directly correlated to known diseases and histological regions allowing the diagnosis and monitoring of disease progression as well predicting the patient’s response to specific treatments. Proteomics performs large-scale, high-throughput characterization of the human proteome, among others by biological mass spectrometry. Proteinchip technology coupled with bioinformatics is able to screen any protein source for putative disease biomarkers from a small sample volume (microliter range) by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). This article discusses on a basic level both the technology and reliability of these methods. Pathology & Oncology Research, Vol 12, Nr 3, 178-183, 2006

Key words: serum proteome; tissue proteome; mass spectrometry; matrix; protein biomarker; SELDI; ProteinChip system; proteomics; genomics

Received: May 4, 2006; accepted: Aug 15, 2006
Correspondence: Károly LAPIS, 1st Institute of Pathology and Experimental Cancer Research, Semmelweis University, Üllõi út 26. Budapest H-1085, Hungary; Tel: 36-1-266-1912, Fax: 36-1-266-1641; E-mail:

Click here to get the full-text version in PDF!